{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:14:17Z","timestamp":1767492857459,"version":"3.48.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-025-04849-7","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:10:22Z","timestamp":1767492622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective monitoring of plasma abemaciclib in breast cancer patients: associations with age and adverse events"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6942-590X","authenticated-orcid":false,"given":"Keisuke","family":"Ikegami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiko Ando","family":"Makihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2127-3601","authenticated-orcid":false,"given":"Yuki","family":"Katsuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsunori","family":"Shimoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4596-5418","authenticated-orcid":false,"given":"Satoko","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"4849_CR1","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40262-017-0559-8","volume":"57","author":"SC Tate","year":"2018","unstructured":"Tate SC et al (2018) A population pharmacokinetic and pharmacodynamic analysis of abemaciclib in a phase I clinical trial in cancer patients. Clin Pharmacokinet 57:335\u2013344. https:\/\/doi.org\/10.1007\/s40262-017-0559-8","journal-title":"Clin Pharmacokinet"},{"key":"4849_CR2","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00280-016-3085-8","volume":"78","author":"Y Fujiwara","year":"2016","unstructured":"Fujiwara Y et al (2016) Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer. Cancer Chemother Pharmacol 78:281\u2013288. https:\/\/doi.org\/10.1007\/s00280-016-3085-8","journal-title":"Cancer Chemother Pharmacol"},{"key":"4849_CR3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s10637-020-00994-3","volume":"39","author":"A Maeda","year":"2021","unstructured":"Maeda A et al (2021) Serum concentration of the CKD4\/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary report. Invest New Drugs 39:272\u2013277. https:\/\/doi.org\/10.1007\/s10637-020-00994-3","journal-title":"Invest New Drugs"},{"key":"4849_CR4","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00228-022-03331-0","volume":"78","author":"A Maeda","year":"2022","unstructured":"Maeda A et al (2022) Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib. Eur J Clin Pharmacol 78:1239\u20131247. https:\/\/doi.org\/10.1007\/s00228-022-03331-0","journal-title":"Eur J Clin Pharmacol"},{"key":"4849_CR5","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00228-020-03014-8","volume":"77","author":"A Mueller-Schoell","year":"2021","unstructured":"Mueller-Schoell A et al (2021) Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol 77:465\u2013465. https:\/\/doi.org\/10.1007\/s00228-020-03014-8","journal-title":"Eur J Clin Pharmacol"},{"key":"4849_CR6","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1053\/j.seminoncol.2024.01.002","volume":"50","author":"D Wekking","year":"2023","unstructured":"Wekking D et al (2023) CDK4\/6 inhibitors in the treatment of metastatic breast cancer: focus on toxicity and safety. Semin Oncol 50:131\u2013139. https:\/\/doi.org\/10.1053\/j.seminoncol.2024.01.002","journal-title":"Semin Oncol"},{"key":"4849_CR7","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.resinv.2013.09.001","volume":"51","author":"K Kubo","year":"2013","unstructured":"Kubo K et al (2013) Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig 51:260\u2013277. https:\/\/doi.org\/10.1016\/j.resinv.2013.09.001","journal-title":"Respir Investig"},{"key":"4849_CR8","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1007\/s12282-020-01207-8","volume":"28","author":"Y Chen","year":"2021","unstructured":"Chen Y et al (2021) Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan. Breast Cancer 28:710\u2013719. https:\/\/doi.org\/10.1007\/s12282-020-01207-8","journal-title":"Breast Cancer"},{"key":"4849_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-024-01648-5","author":"S Nakayama","year":"2024","unstructured":"Nakayama S (2024) Real-world incidence of and risk factors for abemaciclib-induced interstitial lung disease in Japan: a nested case\u2013control study of abemaciclib-induced interstitial lung disease (NOSIDE). Breast Cancer. https:\/\/doi.org\/10.1007\/s12282-024-01648-5","journal-title":"Breast Cancer"},{"key":"4849_CR10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/jjco\/hyac168","volume":"53","author":"C Funasaka","year":"2023","unstructured":"Funasaka C et al (2023) Clinical features of CDK4\/6 inhibitor-related interstitial lung disease in patients with breast cancer: a case series study. Jpn J Clin Oncol 53:105\u2013114. https:\/\/doi.org\/10.1093\/jjco\/hyac168","journal-title":"Jpn J Clin Oncol"},{"key":"4849_CR11","doi-asserted-by":"publisher","first-page":"9869","DOI":"10.1038\/s41598-024-60101-x","volume":"14","author":"S Nakamoto","year":"2024","unstructured":"Nakamoto S et al (2024) Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4\/6 inhibitor efficacy in advanced breast cancer. Sci Rep 14:9869. https:\/\/doi.org\/10.1038\/s41598-024-60101-x","journal-title":"Sci Rep"},{"key":"4849_CR12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12282-025-01680-z","volume":"32","author":"S Nakayama","year":"2025","unstructured":"Nakayama S et al (2025) A prospective cohort study of abemaciclib-induced interstitial lung disease in metastatic breast cancer after chemotherapy. Breast Cancer 32:607\u2013612. https:\/\/doi.org\/10.1007\/s12282-025-01680-z","journal-title":"Breast Cancer"},{"key":"4849_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.breast.2022.02.011","volume":"62","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Ma Z, Sun X, Feng X, An Z (2022) Interstitial lung disease in patients treated with Cyclin-Dependent kinase 4\/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Breast 62:162\u2013169. https:\/\/doi.org\/10.1016\/j.breast.2022.02.011","journal-title":"Breast"},{"key":"4849_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/03602530902722679","volume":"41","author":"U Klotz","year":"2009","unstructured":"Klotz U (2009) Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41:67\u201376. https:\/\/doi.org\/10.1080\/03602530902722679","journal-title":"Drug Metab Rev"},{"key":"4849_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.140836","volume":"304","author":"X Xu","year":"2025","unstructured":"Xu X et al (2025) CYP3A4 activity variations can lead to stratified metabolism of abemaciclib. Int J Biol Macromol 304:140836. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.140836","journal-title":"Int J Biol Macromol"},{"key":"4849_CR16","doi-asserted-by":"publisher","first-page":"2102776","DOI":"10.1183\/13993003.02776-2021","volume":"60","author":"P Spagnolo","year":"2022","unstructured":"Spagnolo P, Bonniaud P, Rossi G, Sverzellati N, Cottin V (2022) Drug-induced interstitial lung disease. Eur Respir J 60:2102776. https:\/\/doi.org\/10.1183\/13993003.02776-2021","journal-title":"Eur Respir J"},{"key":"4849_CR17","doi-asserted-by":"publisher","first-page":"100404","DOI":"10.1016\/j.esmoop.2022.100404","volume":"7","author":"P Conte","year":"2022","unstructured":"Conte P et al (2022) Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO Open 7:100404. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100404","journal-title":"ESMO Open"},{"key":"4849_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10549-022-06738-6","volume":"196","author":"JW Law","year":"2022","unstructured":"Law JW et al (2022) Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis. Breast Cancer Res Treat 196:603\u2013611. https:\/\/doi.org\/10.1007\/s10549-022-06738-6","journal-title":"Breast Cancer Res Treat"},{"key":"4849_CR19","doi-asserted-by":"publisher","first-page":"6027","DOI":"10.21873\/anticanres.16114","volume":"42","author":"A TANIGUCHI","year":"2022","unstructured":"TANIGUCHI A et al (2022) Risk of abemaciclib-induced liver injury in hormone receptor-positive, HER2-negative metastatic breast cancer: a retrospective analysis. Anticancer Res 42:6027\u20136035. https:\/\/doi.org\/10.21873\/anticanres.16114","journal-title":"Anticancer Res"},{"key":"4849_CR20","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s40262-020-00930-x","volume":"59","author":"SL Groenland","year":"2020","unstructured":"Groenland SL et al (2020) Clinical pharmacokinetics and pharmacodynamics of the cyclin-dependent kinase 4 and 6 inhibitors palbociclib, ribociclib, and abemaciclib. Clin Pharmacokinet 59:1501\u20131520. https:\/\/doi.org\/10.1007\/s40262-020-00930-x","journal-title":"Clin Pharmacokinet"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04849-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04849-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04849-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:10:23Z","timestamp":1767492623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04849-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4849"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04849-7","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NY received lecture fees, honoraria, or other fees from Chugai. He received a research funds from Astellas, Chugai, Eisai, Taiho, BMS, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi-Sankyo, Bayer, Boehringer Ingelheim, Kyowa Kirin, Takeda, ONO, Janssen Pharma, MSD, MERCK, GSK, Sumitomo Pharma, Chiome Bioscience, Otsuka, Carna Biosciences, Genmab, Shionogi, TORAY, KAKEN, AstraZeneca, Cmic, InventisBio, Rakuten Medical, Amgen, and Bicycle Therapeutics, Tanabe Mitsubishi, Zymeworks.KS reports honoraria from AstraZeneca, Pfizer, Eisai, Janssen, MSD, Ono Pharmaceutica.KY reports honoraria from Pfizer Inc, Eisai, AstraZeneca, Eli Lilly, Takeda, Chugai, Fuji Film Pharma, PDR Pharma, MSD, Boeringer Ingelheim, Ono, Daiichi-Sankyo, Bayer, Jansen, Asteras, Bristol Myers Squibb, Novartis, Sanofi, and Merk Biopharma; institutional support from MSD, Daiichi-Sankyo, Merk Biopharma, AstraZeneca, Taiho, Pfizer Inc, Novartis, Takeda, Chugai, Ono, Sanofi, Seattle genetics, Eisai, Eli Lilly, Genmab, Boeringer Ingelheim, Kyowa Kirin, Nihon Kayaku, and Haihe; clinical investigator support from MSD, Daiichi-Sankyo, Genmab, Seagen, AstraZeneca, Taiho, Merk Biopharma Pfizer Inc, Novartis, Takeda, Chugai, Ono, Sanofi, Seattle genetics, Eisai, Eli Lilly, Genmab, Boeringer Ingelheim, Kyowa Hakko Kirin, Nihon Kayaku, and Haihe; and has participated on advisory boards for Eisai, Astra Zeneca, Sanofi, Genmab, Gliad, OncXerna, Takeda, Novartis, MSD, and Henlius.No other potential conflicts of interest were reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures performed in this study were approved by the institutional review board of the National Cancer Center (Approval No. 2021\u2009\u2212\u2009386) and followed the ethical principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"3"}}